Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | B3GNT2 | Q9NY97 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808732 | 0.90 | CNR2 (0.37) | B3GNT2CNR2MAPK10AKT1BACE1 | |
| SCHEMBL13129059 | 0.82 | BDKRB1 (0.38) | B3GNT2 | |
| SCHEMBL2810341 | 0.82 | BDKRB1 (0.38) | B3GNT2 | |
| SCHEMBL2810098 | 0.82 | BDKRB1 (0.38) | B3GNT2 | |
| SCHEMBL2810338 | 0.82 | BDKRB1 (0.38) | B3GNT2 | |
| SCHEMBL13129055 | 0.82 | BDKRB1 (0.38) | B3GNT2 | |
| SCHEMBL186430 | 0.81 | BDKRB1 (0.33) | — | |
| SCHEMBL186533 | 0.81 | BDKRB1 (0.33) | — | |
| SCHEMBL2781474 | 0.79 | B3GNT2 (0.33) | B3GNT2OPRM1PDE2ABACE1CACNA1G | |
| SCHEMBL2808439 | 0.78 | BDKRB1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | B3GNT2 2551/4885OPRM1 160/4885PDE2A 1029/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | B3GNT2 2551/4885OPRM1 160/4885PDE2A 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.